Main > > >MYOCARDIAL.

---

Cardio.>Aspirin. MI Prevention? Compa- nion DIAG.:
11-DeHydro Thromboxane B2 ELISA Urine
Test.
USA Approval Date: 2007. 05.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.18.




Cardio.>Aspirin+OmeprAzole Delayed Release Tablets.
Indications:
Aspirin Component:
. Reducing the combined risk of death
and nonfatal MI in patients with a
previous MI or unstable angina
pectoris
. Reducing the combined risk of MI and
sudden death in patients with chronic
stable angina pectoris
. Use in patients who have undergone
revascularization procedures (Coronary
Artery Bypass Graft [CABG] or
Percutaneous Transluminal Coronary
Angioplasty [PTCA]) when there is a
pre-existing condition for which
aspirin is already indicated
OmeprAzole Component:
. decreasing the risk of developing
aspirin-associated gastric ulcers in
patients at risk for developing
aspirin-associated gastric ulcers due
to age (≥ 55) or documented history of
gastric ulcers.
USA Approval Date: 2016. 09.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.18.




Cardio.>Infarction. Acute ST-Segment Elevation Myocardial Infarction [STEMI]. Prevention. Secondary Prevention:
Fondaparinux Sodium.
Synthetic Heparin.
Xa Inhibitor.
(*) Company : Aspen Holdings.
www.aspenpharma.com
Patent : Expired.
TradeMark: Arixtra.
Web-Site :
www.aspenpharma.com/thrombosis/
UpDate: 2018. 02.04.




Cardio.>Infarction. Acute ST-Segment Elevation Myocardial Infarction [STEMI]. Prevention. Secondary Prevention:
Rivaroxaban Tablets.
Xa Inhibitor.
EU Approval Date : 2013. 05.24.
USA Approval Date: 2012. 11.02.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 02.04.




Cardio.>Infarction. Acute ST-Segment Elevation Myocardial Infarction [STEMI]. TREAT.: Enoxaparin Sodium Injection.
BRAND.
low molecular weight heparin [LMWH]
Patent Expiration: 2004.
(*) Company : Sanofi Aventis US LLC
TradeMark: Lovenox
Web-Site : www.lovenox.com
UpDate: 2018. 01.31.




Cardio.>Infarction. Acute ST-Segment Elevation Myocardial Infarction [STEMI]. TREAT.: Enoxaparin Sodium Injection.
GENERIC.
low molecular weight heparin [LMWH]
USA Approval Date: 2010. 07.
(*) Company : Momenta Pharmaceuticals
Web-Site: www.momentapharma.com/products/enoxaparin.php
UpDate: 2018. 01.31.




Cardio.>Infarction. Cause: Unstable Cardiac Lesion Rupture. DIAG.: Predictive Cardiac Blood Test.
The Test Predicts within 5-Years Time Whether an Individual
will have a Heart Attack ..
Launch Date: 2018. 02.27.
(*) Company : SQI Diagnostics Inc.
sqidiagnostics.com
TradeMarks: PULS.
sqidlite
Web-Sites : www.pulstest.com/
sqidiagnostics.com/systems/sqidlite
UpDate: 2018. 03.04.




Cardio.>Infarction. Non–Q-Wave Myocardial Infarction.
Ischemic Complications Prevention: Enoxaparin Sodium Injection. BRAND.
low molecular weight heparin [LMWH]
Patent Expiration: 2004.
(*) Company : Sanofi Aventis US LLC
TradeMark: Lovenox
Web-Site : www.lovenox.com
UpDate: 2018. 01.31.




Cardio.>Infarction. Non–Q-Wave Myocardial Infarction.
Ischemic Complications Prevention: Enoxaparin Sodium Injection. GENERIC.
low molecular weight heparin [LMWH]
USA Approval Date: 2010. 07.
(*) Company : Momenta Pharmaceuticals
Web-Site: www.momentapharma.com/products/enoxaparin.php
UpDate: 2018. 01.31.




Perfusion Imaging Agent.
(*) Company : GE Healthcare.
Patent : Expired.
TradeMark: MyoView.
UpDate: 2019. 03.29.






>MYOCARDIAL.'s products
This section has no products